Inovio Pharmaceuticals, Inc.
A maker of DNA-based vaccines and medicines that teach the body's own cells to fight disease. The company designs synthetic DNA instructions and delivers them with its hand-held CELLECTRA device, whose brief electrical pulses open tiny pores in cells to target cancers and HPV-related conditions. Founded in 1983 as Biotechnologies & Experimental Research, it later operated as Genetronics and took its current name after acquiring the Norwegian gene-delivery firm Inovio in 2005.
Granted 271.9K
Granted 489.2K
Granted 129.0K · Sold 46.5K
Granted 337.8K
Granted 287.5K
Granted 83.3K
Granted 47.3K · Sold 6.0K
Granted 41.3K
Granted 45.6K
Granted 49.9K
Granted 48.3K
Granted 45.4K · Sold 10.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kim Jong JosephChief Executive Officer, Director · 6 transactions | +5.4% | 2.35Mas of Mar 2022 | 271.9K | — | — |
| Shea Jacqueline ElizabethChief Executive Officer, Director · 38 transactions | +414.2% | 111.0K | 489.2K | — | — |
| Weiner David B.Director · 23 transactions | -89.8% | 87.6K | 129.0K | — | 46.5K |
| Humeau LaurentChief Scientific Officer · 34 transactions | -28.6% | 49.0K | 337.8K | — | — |
| Kies PeterCFO · 32 transactions | -71.7% | 47.9K | 287.5K | — | — |
| Sumner Michael JohnChief Medical Officer · 16 transactions | — | 42.0K | 83.3K | — | — |
| Benito Simon XDirector · 10 transactions | -78.7% | 12.2Kas of May 2025 | 47.3K | — | 6.0K |
| Yarno Wendy LDirector · 4 transactions | -71.7% | 10.5Kas of May 2025 | 41.3K | — | — |
| Miller Ann CalbyDirector · 5 transactions | -60.9% | 9.9Kas of May 2025 | 45.6K | — | — |
| Shepard JayDirector · 6 transactions | -29% | 9.2Kas of May 2025 | 49.9K | — | — |
| Dansey Roger DDirector · 6 transactions | — | 8.9Kas of May 2025 | 48.3K | — | — |
| Zoth Lota S.Director · 8 transactions | -60.1% | 8.7Kas of May 2025 | 45.4K | — | 10.3K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -62.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.